Sustaining member of Paul-Ehrlich-Society for Chemotherapy e.V. (PEG)

MERLIN is a sustaining member of the well-known German Paul-Ehrlich-Society for Chemotherapy e.V. (PEG) for many years. We are actively engaged in various studies initiated and conducted by PEG. Above all, we are concerned with the resistance-studies, which use our in-vitro testing systems.

Member in the German Association of the Diagnostica Industry (VDGH)

For many years MERLIN is being a very active member of Germany’s association of the diagnostics industry (VDGH). The VDGH offers us the platform for the professional exchange with other Diagnostica manufacturers for research, development, production and distribution of laboratory analytical products. We listen attentively to what analytics in the lab business requires in order to continuously optimize our products and the automated workflow. The market research results of the VDGH working groups are also valuable for our work, which confirm us where the IVD market is developing.

Sustaining member in DELAB

MERLIN is a sustaining member of the German DELAB e.V. for many years. We are pleased to support this association of laboratory specialists, specialists in microbiology and scientists with our comprehensive expertise in in-vitro diagnostics.


UMIC® Cefiderocol

31.08.2022  |  From a drug development perspective, cefiderocol is one of the most promising antibiotics, remaining active even when facing the most challenging carbapenem resistance mechanisms. To support antibiotic stewardship, clinical microbiologists are looking for reliable and accurate cefiderocol MIC testing in full compliance with EUCAST and CLSI standards. Bruker's UMIC® Cefiderocol and the associated iron-depleted Mueller Hinton broth offer an easy to implement solution and can conveniently be tested along with UMIC® Colistin to deliver trusted MIC results when it matters most.

For more information, please visit Bruker's website.

Legal Manufacturer Change

From January 2022 the MICRONAUT products have been transferred from MERLIN Gesellschaft fuer mikrobiologische Diagnostika mbH to Bruker Daltonics GmbH & Co. KG as legal manufacturer.

EUCAST warns against the use of vancomycin gradient tests for MIC determination!

21.05.2019  |  EUCAST warns against the use of gradient tests for vancomycin MIC determination, since this causes false susceptibility. EUCAST recommends products based on broth microdilution procedure as method of choice for vancomycin MIC determination to confirm vanB low-level resistance in Enterococcus faecalis and Enterococcus faecium. (ref. MIC-Strip Vancomycin/Teicoplanin).
More information about the difficulties in the EUCAST vancomycin susceptibiliy testing

NEW | MICRONAUT-S Carbapenemases Detection

11.09.2018  |  The new two-test-plate MICRONAUT-S Carbapenemases Detection, which is based on broth microdilution procedure, provides phenotypic detection of clinically relevant carbapenemases (type A carbapenemases (e.g. KPC), metallo-β-lactamases, and OXA-48-like type D carbapenemases) in enterobacteria and Pseudomonas aeruginosa.

  • NEW: Phenotypic confirmatory assay of OXA-48-like type D carbapenemases in enterobacteria by the new inhibitor combination meropenem / avibactam and determination of high-level temocillin resistance.
  • Two isolates can be tested per plate.

The layout of this special plate is available on request.

Dr. Esther Pfeil elected as a member of the German CCI General Assembly

01.01.2017  |  Last autumn, Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika GmbH, took part in the election to the General Assembly of the chamber of commerce and industry Bonn / Rhein-Sieg. Since January 1st, 2017, she is representing the interests of the manufacturing industry in the Rhein-Sieg area for five years at the General Assembly. Dr. Pfeil decided to present herself as a candidate "since I am a managing director of an SME, I would like to take responsibility for the strengthening of small and medium-sized enterprises (SMEs) and their employees in our region. Subjects, of which I feel touched and which I would like to move forward, are the enhancement of market ability through innovation, the expansion of existing training and development programs to promote skilled workers, and the reconcilability of family and work."



EUCAST warning regarding Colistin susceptibility testing

28.11.2016 | Thanks to our microdilution procedure, EUCAST recommends our MICRONAUT products for Colistin testing!

More information about the difficulties in the EUCAST Colistin susceptibility testing

MICRONAUT-UR | update with the new antibiotic Mecillinam

19.10.2016  |  The plate MICRONAUT-UR, which is used in the bacteriological laboratory diagnostics for urology, is from now on available with an improved antibiotics spectrum. It has been enriched by the new antibiotic Mecillinam.

NRW subsidies for the joint research project "PathoSept"

MERLIN is among the winners in the key market competition LifeSciences.NRW

01.08.2016 | MERLIN Diagnostika is one of the winners of the first round in the key market competition LifeSciences.NRW: Referees voted for the joint research project "PathoSept", which is intended to save many lives by rapidly diagnosing threatening infections.

In the key market competition LifeSciences.NRW, 10 joint projects were selected from 51 contest entries, which will be funded with a total of 19.3 million euros.

"Winner is also our project 'PathoSept', with which we want to create a diagnostic complete system under the coordination of the Fraunhofer Institute for Applied Information Technology. It very quickly identifies pathogenic agents of life-threatening infections and simultaneously allows a quantitative determination of the antibiotic resistance profile. Based on these results, it can be initiated a targeted individual antibiotic therapy no later than nine hours", says Dr. Esther Pfeil, Managing Director of MERLIN Diagnostika.

In addition to the Fraunhofer Institute and MERLIN, the companies Carpegen GmbH, based in Münster, and Jüke Systemtechnik GmbH as well as the university clinics of Aachen and Bonn, belong to the network. The volume of this project is about 3.5 million euros.

Every year, more than 56,000 people die from sepsis in Germany, one of the most severe bacterial infections that can be even simply caused by a purulent tooth. Currently, the time between suspected diagnosis and targeted therapy can last up to five days, and infections with multiresistant pathogens can not be adequately treated. PathoSept is intended to open up the reliable diagnosis after nine hours, thus significantly reducing the high mortality rate, but above all the new generation and spread of multiresistant pathogens, as well as the intensive medical costs. With this an infection can be treated very early in the process and very specifically.

MERLIN has already made essential preparations for this project because we are specialized in the development, validation and marketing of various microbiological diagnostic systems for the qualitative and quantitative detection of microbial antibiotic resistance. MERLIN's diagnostic systems for quantitative susceptibility testing allow the determination of the minimum inhibitory concentration (MIC value) in accordance with the normative requirements. These systems are supplemented by phenotypic detection methods for the detection of clinically and epidemiologically relevant resistance mechanisms. MERLIN also has a great expertise in the handling of antimicrobial agents, which are meaningful in the validation of the manufacture, packaging, storage and application of antibiotic-containing diagnostics. "These are core competencies that make a decisive contribution to the successful implementation of the joint research project," emphasizes Dr. Esther Pfeil.

MERLIN is continuing the development of its products and processes, taking into account sustainability as well as environmental and economic aspects, with the aim of implementing the Antibiotic Stewardship for the rational use of the anti-infectives.



MICRONAUT-S | first AST product with the new antibiotics combinations of Ceftazidim/Avibactam and Ceftolozan/Tazobactam

24.05.2016 | MICRONAUT-S MDR MRGN Screening, the updated MIC plate for the susceptibility testing of multi-resistant gramnegative bacteria (multidrug resistance phenotype), has been enriched with these new features:

  • Expanded antibiotic spectrum by introducing the new antibiotic combinations Ceftazidim / Avibactam and Ceftolozan / Tazobactam
  • Expanded antibiotic spectrum by introducing Meropenem screening concentrations for improved detection of OXA-48-like type D carbapenemases

MICRONAUT-S MDR MRGN Screening provides, based on the microdilution method, the phenotypic detection of clinically relevant resistance mechanisms in enterobacteria and nonfermenters, including the detection of cephalosporinases and carbapenemases.

MICRONAUT-S ß-Lactamases | optimized detection of OXA-48

16.03.2016 | The phenotypic detection of multiple ß-lactamases (multiple resistance determinants) in the single test system has been extended:

MICRONAUT-S β-Lactamases provides, based on the microdilution method, the phenotypic detection  of clinically relevant cephalosporinases and carbapenemases in entero-bacteria and non-fermenters.

  • Detection of OXA-48-like type D carbapenemases by the determination of high-level Temocillin resistance
  • Detection of low-level carbapenem resistance by introduction of Ertapenem / Meropenem screening concentrations

The layout of these special plates is available upon request.